Cogent Biosciences, Inc. COGT Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$354.3M-7.7% | -$328.94M-11.7% | -$294.37M-3.6% | -$284.08M-5.4% | -$269.5M-5.3% | ||
| $2.55M-0.5% | $2.56M+0.1% | $2.56M+0.8% | $2.54M+2.0% | $2.49M+1.7% | ||
| $52.98M+15.0% | $46.08M+14.3% | $40.31M+0.6% | $40.06M-0.7% | $40.36M+1.5% | ||
| $879K+46.3% | $601K+65.6% | $363K+476% | $63K— | $0— | ||
| —— | —— | —— | —— | $0— | ||
| -$410K+83.7% | -$2.51M— | —— | —— | —— | ||
| $9.14M-14.4% | $10.69M+47.5% | $7.25M-24.5% | $9.6M-31.5% | $14.02M-12.1% | ||
| $4.2M+2,055% | $195K-43.5% | $345K— | —— | —— | ||
| $57K+72.7% | $33K+65.0% | $20K+122% | $9K+80.0% | $5K— | ||
| $2.05M+1.5% | $2.02M+1.5% | $1.99M+1.5% | $1.96M+1.4% | $1.93M+1.6% | ||
| —— | -$7.18M-33.3% | -$5.39M-50.0% | -$3.59M-100% | -$1.8M— | ||
| -$284.82M-7.7% | -$264.44M-7.5% | -$245.92M-5.3% | -$233.61M-5.3% | -$221.77M-6.7% | ||
| $1.46M-6.3% | $1.55M+90.0% | $818K-20.8% | $1.03M-1.6% | $1.05M+83.2% | ||
| -$505.36M-26.5% | -$399.53M-2,548% | -$15.09M-108% | $200.15M+87.7% | $106.61M+179% | ||
| —— | $54.64M+33.3% | $40.98M+50.0% | $27.32M+100% | $13.66M— | ||
| $17.17M+48.7% | $11.55M+874% | $1.19M+740% | $141K+3.7% | $136K— | ||
| —— | $48.9M+33.3% | $36.67M+50.0% | $24.45M+100% | $12.22M— | ||
| $905.8M+3.1% | $878.23M+203% | $289.59M+298% | $72.85M+184% | $25.62M-88.1% | ||
| $117.59M-45.6% | $216.23M+608% | $30.55M-22.4% | $39.38M— | —— | ||
| —— | —— | —— | —— | $7.18M-5.8% | ||
| $879K+46.3% | $601K+65.6% | $363K+476% | $63K— | $0— | ||
| —— | $2.56M+1.1% | $2.54M+1.1% | $2.51M+1.1% | $2.48M+1.2% | ||
| $9.14M-14.4% | $10.69M+47.5% | $7.25M-24.5% | $9.6M-31.5% | $14.02M-12.1% | ||
| -$1.61M-2.9% | -$1.57M-3.0% | -$1.52M-3.1% | -$1.48M-3.0% | -$1.43M-3.3% | ||
| -$2.92M-87.2% | -$1.56M-313% | -$378K— | —— | —— | ||
| $4.2M+2,055% | $195K-43.5% | $345K— | —— | —— | ||
| $2.05M+1.5% | $2.02M+1.5% | $1.99M+1.5% | $1.96M+1.4% | $1.93M+1.6% | ||
| —— | $223.1M+33.3% | $167.33M+50.0% | $111.55M+100% | $55.78M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $24.25M— | ||
| —— | $54.64M+33.3% | $40.98M+50.0% | $27.32M+100% | $13.66M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $79K— | ||
| -$286.27M-7.6% | -$266M-7.8% | -$246.73M-5.2% | -$234.65M-5.3% | -$222.82M-6.9% | ||
| -$286.27M-7.6% | -$266M-7.8% | -$246.73M-5.2% | -$234.65M-5.3% | -$222.82M-6.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cogent Biosciences, Inc. generate?
- Cogent Biosciences, Inc. (COGT) generated -$284.8M in operating cash flow over the trailing twelve months.
- What is Cogent Biosciences, Inc.'s free cash flow?
- After $1.5M of capital expenditures, Cogent Biosciences, Inc.'s free cash flow was -$286.3M over the trailing twelve months, down 28.5% year over year.
- Where does Cogent Biosciences, Inc.'s cash flow data come from?
- Every line is extracted from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
